Maze Therapeutics is a clinical-stage biopharmaceutical company focused on its Compass platform and lead therapeutic candidates MZE829 and MZE782. As of November 4, 2026, the company had 54,683,345 shares of common stock outstanding and continues to report significant operating losses with no product revenue generated to date.
Maze Therapeutics reported third quarter 2026 financial results, ending the period with $477 million in cash and a projected runway into 2029. The company highlighted the completion of enrollment for its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease, with data expected in early 2027. Net loss for the quarter was $38.4 million, driven by increased R&D expenses related to its clinical-stage pipeline.
Term
Q3 2026
“Completing enrollment in HORIZON with more than 50 patients across three cohorts marks an important milestone for MZE829 and exceeded our target enrollment of 10-15 patients per cohort. HORIZON gives us the opportunity to generate a robust dataset across three distinct AMKD patient populations, including patients with and without diabetes and those with FSGS, and provide a comprehensive view of MZE829’s potential as a best-in-class therapy for a broad AMKD population, supported by its differentiated dual mechanism of action.”
Jason Coloma, Ph.D., chief executive officer of Maze
Maze Therapeutics CEO Jason V. Coloma Sells $1.04M of Stock
Jason V. Coloma, CEO, sold 34,501 shares of Maze Therapeutics, Inc. at $30.09 to $31.05 a share (average $30.25) in 4 transactions, worth $1.04M in total on Nov 2, 2026. Shares held after the trade: 186,901 (-2.8%).
Maze Therapeutics Csbo Atul Dandekar Sells $241K of Stock
Atul Dandekar, Csbo, sold 7,500 shares of Maze Therapeutics, Inc. at $32.07 a share, worth $241K in total on Oct 29, 2026. Shares held after the trade: 32,316 (-18.8%).